BANNOCKBURN, Ill., July 10 /PRNewswire/ -- Pinnacle Biologics, a private, full-service pharmaceutical and biotech solutions company today announced it has entered into an agreement with pharmexx to expand sales support activities in a number of countries in Western Europe. Terms of the agreement were not disclosed.
Viren Grover, Vice-Chairman of Pinnacle Biologics Inc. stated, "We are pleased to conclude this agreement with pharmexx, which allows us a cost effective way to support our sales and marketing activities for Ethyol (R) in key European markets where we believe there is upside potential."
Georg Nagl, CEO of pharmexx said, "pharmexx is delighted to be working with Pinnacle on their new venture in Europe. Our businesses are a good fit and provide an ideal win/win opportunity; we look forward to a long and successful relationship."
About Pinnacle Biologics
Founded in 2007 by former Abbott Laboratories executives Guillermo Herrera, Viren Grover, and James R. Miller, Pinnacle Biologics is a premier international company that excels in assisting pharmaceutical and biotech companies that require a total solution in either launching products or maximizing/monetizing the value of products late in their life cycle. Pinnacle forms exclusive relationships with research-based pharmaceutical multi-national corporations and biotechnology companies to take products to the next level.
Pinnacle provides a full range of services including regulatory, sales, marketing, distribution (including billings and collections), pharmacovigilence, product safety, market research and administrative services.
Pinnacle holds executive offices in Bannockburn, Illinois, satellite offices in Rockville, Maryland, and Almere, The Netherlands. Further information is available at http://www.pinnaclebiologics.com
pharmexx is one of the leading contract sales o
|SOURCE Pinnacle Biologics|
Copyright©2008 PR Newswire.
All rights reserved